BTNL2 and neoplasm: Following depletion of CD8+ T cells in tumour-bearing mice using anti-CD8a neutralizing antibody, the anti-tumour effect of anti-BTNL2 treatment was completely abolished, indicating that CD8+ T cells are the major tumour-cytotoxic cell following BTNL2 blockade (Fig. 4h, i).